14 November 2025
Psychedelic Lived Experiences: The Missing Expertise in Psychedelic Care
Why participants should be co-authors of research, training, and care, not just subjects of study.
By: Pedram Dara
MAPS Bulletin: Volume XXXIV
I enrolled as a participant in the Phase 2 clinical trial for MDMA-assisted therapy for PTSD in late 2018. By my two-month follow-up in the summer of 2019, psychedelics had gone from fringe to front page.
Given that I had a mostly favorable experience with the treatment, like most early trial participants, I wanted to share it so others could find the hope I had once needed.
A few months later, and exacerbated by the impact of the pandemic, I had my first major relapse. Without access to any further integration or peer support, I found myself in an isolating situation where I needed more help than was available. I wanted to connect with other trial participants so badly, but I didn’t know anyone. That’s the nature of clinical research, where participants are left to their own devices.
I struggled for months. Thanks to my wife, a few friends, and others who went out of their way, I got back up again. But I suffered needlessly. There was no aftercare infrastructure. It felt like getting surgery with no recovery plan.
Through my own post-treatment challenges, I realized the advocacy work I needed to do was not about expanding access; it was about improving how treatments are designed, delivered, and, most importantly, how they are ended.
And what better way to improve something than by getting direct feedback from those most impacted by it? I knew that from working in product management. In tech, the end users are the boss; their usage data drives priorities and continuous improvement.
When building software, ignoring users leads to churn—people stop using your product. In clinical research, it means losing people’s trust—and sometimes, their safety.
Yet when I found myself as a “user” in psychedelic research, I realized the people most affected by these treatments have been the least visible in shaping how they’re designed, delivered, evaluated, taught, or understood.
Patients’ lived experiences rarely appear in clinical research papers, training program curricula, or conference programs.
Meanwhile, mainstream healthcare fields like oncology, chronic pain, and behavioral health have integrated “patient partners,” peer support specialists, and “lived experience advisors” for decades.
Despite psychedelic medicine’s reputation as a revolution in empathy and transformation, its systems of authority still privilege credentials and institutional power over those who have lived experience receiving psychedelic-assisted therapy.
What would psychedelic care look like if lived experience were recognized as legitimate expertise?
How Psychedelic Science Defined Knowledge
From the 1950s to today, psychedelic research has defined legitimacy through biomedical frameworks. Credentials and measurable outcomes have the ultimate authority. Lived experience became “anecdotal,” meaning it is only useful for storytelling, not shaping evidence.
The so-called “psychedelic renaissance” amplified this bias: patient stories were welcomed as marketing, not as study methods, and complex healing arcs did not make headlines. Media outlets favored the statistically tidy, percentage improvements, and “breakthrough” labels over messy qualitative accounts of slow, non-linear recovery.
While books like How to Change Your Mind helped destigmatize psychedelics, they over-indexed on miracle narratives that create unrealistic expectations drawn from short-term outcomes measured during the early post-treatment “honeymoon phase,” before longer-term integration challenges often surface.
We need the rest of the dataset – what helped, what hurt, and what happened – to create a realistic understanding of what these treatments offer outside of the headlines. This narrative imbalance leaves both enthusiasm and critique unmoored from authentic and diverse participant experience.
The Cost of Silence
When lived experience expertise is absent, you not only miss the emotional subjectivity, you miss the bugs in the system. Without structured pathways to share and interpret these stories, key lessons are lost and potential harms are ignored.
Healing trajectories are diverse: some people experience profound benefit, while others are left with confusion or distress. Yet public stories still pretend it’s one-size-fits-all.
Media cycles reward extremes, either miracles or disasters, flattening the complex and nuanced reality in between. Educational programs rarely train clinicians to treat lived experience as data, even though these stories could strengthen both safety and understanding of the therapeutic process.
The individuals who have actually undergone these treatments hold the most relevant insights grounded in lived reality, providing a fuller picture that data points and outside observers can only approximate. Yet, at best, their presence is tokenized, and, at worst, altogether missing from the tables where research, treatment, and policy decisions are made.
Even when the participants are present, their voices are often drowned out by professional and institutional authorities, limiting the influence of those most directly impacted by these treatments.
Founding Psychedelic Lived Experiences
After years of advocacy and dialogue, it became clear that a bridge was missing between the realities of participants and institutional decision-making. I realized randomized clinical trials are excellent for pills–but they are clumsier with people.
On June 4, 2024, during the FDA’s advisory committee meeting on the Phase 3 trials of MDMA-assisted therapy for PTSD, I was given a three-minute slot to speak – not because anyone asked, but because I believed lived experience needed a voice in the room. My story and insights, along with my fellow trial participants, were visible but not valued. Quantitative data dominated. Human stories were absent.
The meeting aimed to assess benefits and risks, yet those who received the treatment had no dedicated seat at the table; the same three-minute slot opportunity was offered to anyone in the world with an opinion. There was no dedicated time or space on the agenda for actual trial participants to speak about their lived experiences.
That day, I wasn’t discouraged by the FDA’s decision so much as by realizing how little space our system gives to the human side of science. Data outweighed stories, and trial participants, the very “users” of these treatments, had no real voice. In tech, we’d call that a failure of user-centered design.
Watch on the Virtual Trip
That same day, I decided to launch Psychedelic Lived Experiences, a patient-led initiative that seeks to turn lived experience from “subject of study” into “source of guidance.”
With the goal of bridging clinical science and lived expertise with nuance and wisdom, the first-ever virtual Psychedelic Lived Experiences Summit is taking place on November 21 – 23, 2025, for free. With a focus on knowledge exchange, community building, storytelling, and shared learning, this Summit is a global gathering of 50+ diverse patients, trial participants, seasoned clinicians, and researchers. It’s a space where individuals with firsthand experience can inform science and training from the inside out.
Lessons for a More Mature Field
Psychedelic research, treatment, and policy must mature into a more collaborative model where evidence and experience are equal partners. Mainstream healthcare already offers blueprints, from Canada’s Patient-Oriented Research Networks to the UK’s National Institute for Health and Care Research, to demonstrate how embedding patients’ perspectives improves ethics and trust.
To integrate psychedelics responsibly, we should:
- Create formal roles for lived experience experts in clinical research, therapy practices and trainings, and policymaking institutions.
- Conduct and integrate qualitative data alongside quantitative data in a meaningful way.
- Establish continuous feedback loops and maintain long-term follow-up with the participants.
- Train clinicians and researchers to learn from participants, not just treat them.
This is not anti-science. It is better science, grounded in humility and real-world outcomes.
From Evidence to Understanding
Psychedelic therapy is reshaping mental healthcare, but clinical expertise and data alone cannot capture all the layers of healing that lived experience reveals.
Those firsthand perspectives offer a kind of wisdom that bridges research and reality–if we let them. True progress depends on listening differently: people with lived and living experience should be co-authors, not just data points.
On that June day, I realized the work ahead was not only about access to the treatment but also access to the voices of those with lived experiences in the psychedelic-assisted therapy trials.
I am now committed to this mission to build a future where clinical excellence and lived wisdom coexist, where healing is measured not just by symptom reduction, but by the restoration of meaning and agency within a biopsychosocial model.
We don’t need another psychedelic renaissance. We need a maturation, one grounded in humility, accountability, and lived experience.
Pedram Dara
Pedram Dara is a former MDMA-assisted therapy clinical trial participant and the founder and director of Psychedelic Lived Experiences, a patient-led initiative advancing lived experience expertise in psychedelic research, treatment, and policy. Since 2019, he has combined his 15+ years of experience producing media, building products, and connecting people across disciplines with a passionate commitment to patient safety and treatment efficacy. Pedram has shared his insights at major forums, including the European Parliament, the U.S. FDA, and international conferences such as Psychedelic Science, ICPR, and Breaking Convention. His story and expertise have been featured in documentaries, training programs, news media, and scientific journals, including Nature Medicine. He is pioneering a new model that bridges clinical science and lived expertise through training and empowering those with firsthand experience to shape research, practice, policy, education, ethics, and community healing, building a future informed by both evidence and experience in psychedelic care.
Become a MAPS Member with a monthly donation
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.